Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY 67 Shiller PE Ratio is 50.54 as of Aug. 06, 2026, which is 15% above its 10-year median of 43.96. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $18.46 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 535 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 79.81% on this metric.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Shiller PE Ratio or its related term are showing as below:
SWOBY'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 28.96 Med: 43.96 Max: 545.59
Current: 50.54
During the past years, Swedish Orphan Biovitrum AB's highest Shiller PE Ratio was 545.59. The lowest was 28.96. And the median was 43.96.
SWOBY's Shiller PE Ratio is ranked worse than 79.81% of 535
companies
in the Drug Manufacturers industry
Industry Median: 25.04
vs SWOBY: 50.54
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Jun. 2026 was $0.165. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.46 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Swedish Orphan Biovitrum AB Shiller PE Ratio Related Terms
Swedish Orphan Biovitrum AB Shiller PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB Shiller PE Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Shiller PE Ratio falls into.
Swedish Orphan Biovitrum AB Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Swedish Orphan Biovitrum AB (SWOBY) has a Shiller PE Ratio of 50.54 as of Aug. 06, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 15% above median its historical median of 43.96. Over the past decade, Swedish Orphan Biovitrum AB's Shiller PE Ratio has ranged from 28.96 to 545.59. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #427 out of 535 companies in the Drug Manufacturers industry, placing it in the top 79.8%.
Is Swedish Orphan Biovitrum AB's Shiller PE Ratio too high?
Swedish Orphan Biovitrum AB's current Shiller PE Ratio of 50.54 is 15% above median its 10-year median of 43.96. Over the past 10 years, this metric has ranged from a low of 28.96 to a high of 545.59. The Drug Manufacturers industry median Shiller PE Ratio is 25.04. Swedish Orphan Biovitrum AB's value of 50.54 is 101.8% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #427 out of 535 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Shiller PE Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #427 out of 535 companies for Shiller PE Ratio. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median Shiller PE Ratio is 25.04. Swedish Orphan Biovitrum AB's value of 50.54 is 101.8% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own Shiller PE Ratio has ranged from 28.96 to 545.59 over the past decade. While the company's 10-year median is 43.96 vs. the industry median of 25.04, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.04, based on 535 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Shiller PE Ratio of 50.54 is 101.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Shiller PE Ratio is 50.54, which is 15% above median its own 10-year median of 43.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $18.46, compared to a current price of $23.25 — trading 25.9% above its estimated fair value. The current Shiller PE Ratio is 50.54, which is 15% above median its 10-year median of 43.96 and 101.8% above the Drug Manufacturers industry median of 25.04. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Shiller PE Ratio is 50.54 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.25 is trading 25.9% above its estimated GF Value™ of $18.46.
GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.
Key valuation signals for SWOBY:
Shiller PE Ratio: 50.54 (15% above median its 10-year median of 43.96)
GF Value™: $18.46 vs. price of $23.25 (25.9% above fair value)
Industry Position: 101.8% above the Drug Manufacturers median (#427 of 535)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
